Supporters of the Foundation since its inception, Jane and Dorothy Batten have advanced the field of focused ultrasound immeasurably through their philanthropy and conviction in the potential of the technology.
June is Cancer Immunotherapy Month.Look for this icon below for the latest in this field.
Foundation News
Register for Two Upcoming Webinars for Cancer Immunotherapy Month
On June 17, the University of Pennsylvania’s Stephen Bagley, MD, MSCE, will discuss liquid biopsy for brain tumors. REGISTER NOW >
On June 24, Cancer Research Institute CEO Jill O’Donnell-Tormey, PhD, will discuss cancer immunotherapy research and treatment during the pandemic. REGISTER NOW >
Scott Beardsley, Dean of the University of Virginia Darden School of Business, and Mike Lincoln, Global Business Department Chair at the international law firm Cooley LLP, have joined the Foundation’s Board of Directors.
Two valued members of the Foundation's family have been elected to the Board of Directors for the International Society for Therapeutic Ultrasound (ISTU).
We are saddened to share the passing of a leader in the focused ultrasound community, Dr. Todd Mainprize, Division Head of Neurosurgery at Sunnybrook Health Sciences Centre.
After much consideration for the wellbeing of our participants during the current public health crisis, we have made the difficult decision to hold this year's Symposium virtually.
The Core Hub for Medical Research of UltraSound (CHORUS) is a focused ultrasound research facility at Seoul National University Hospital with a mission to make a better world using ultrasound.
We're asking for your input to create a set of guidelines to help standardize focused ultrasound treatment reporting and methodologies for measuring and describing key parameters for preclinical and clinical investigations.
Several presentations at the New York Academy of Sciences' “Frontiers in Cancer Immunotherapy 2020” online symposium covered areas where focused ultrasound combined with immunotherapies could improve therapeutic outcomes.
A research team led by a former Foundation Research Fellow published a promising study that used focused ultrasound to activate, or “sonosensitize,” a nontoxic chemical agent.
E&I has been working behind the scenes of the focused ultrasound industry for 16 years to build the “rugged and reliable” RF amplifiers that launch new ideas and new companies.
SonaCare has announced new study results suggesting that focal ablative salvage therapy after radio-recurrent prostate cancer is safe and provides good cancer control.
HistoSonics has closed a $40 million Series C-1 financing round led by Yonjin Venture, LLC. The financing will be used to accelerate activities focused on HistoSonics’ Edison™ Platform and launch new strategic projects.
In lieu of their annual half marathon fundraiser, the Chordoma Foundation’s #TeamChordoma is asking people to complete their own 5K, donate, and nominate five people to do the same.
